List of Bulk Drug Substances That May Be Used by an Outsourcing Facility To Compound Drugs for Use in Animals; Request for Nominations; Correction

---
identifier: "/us/fr/2015-15558"
source: "fr"
legal_status: "authoritative_unofficial"
title: "List of Bulk Drug Substances That May Be Used by an Outsourcing Facility To Compound Drugs for Use in Animals; Request for Nominations; Correction"
title_number: 0
title_name: "Federal Register"
section_number: "2015-15558"
section_name: "List of Bulk Drug Substances That May Be Used by an Outsourcing Facility To Compound Drugs for Use in Animals; Request for Nominations; Correction"
positive_law: false
currency: "2015-06-25"
last_updated: "2015-06-25"
format_version: "1.1.0"
generator: "[email protected]"
agency: "Health and Human Services Department"
document_number: "2015-15558"
document_type: "notice"
publication_date: "2015-06-25"
agencies:
  - "Health and Human Services Department"
  - "Food and Drug Administration"
fr_citation: "80 FR 36543"
fr_volume: 80
docket_ids:
  - "Docket No. FDA-2015-N-1196"
fr_action: "Notice; correction."
---


#  List of Bulk Drug Substances That May Be Used by an Outsourcing Facility To Compound Drugs for Use in Animals; Request for Nominations; Correction

**AGENCY:**

Food and Drug Administration, HHS.

**ACTION:**

Notice; correction.

**SUMMARY:**

The Food and Drug Administration is correcting a notice entitled “List of Bulk Drug Substances That May Be Used by an Outsourcing Facility to Compound Drugs for Use in Animals; Request for Nominations” that appeared in the *Federal Register* of May 19, 2015 (80 FR 28622). The document announced the intention to develop a list of bulk drug substances that may be used by outsourcing facilities registered under the Federal Food, Drug, and Cosmetic Act (the FD&C Act) to compound animal drugs, in accordance with FDA's draft guidance for industry #230, “Compounding Animal Drugs from Bulk Drug Substances.” The document was published with an incorrect docket number. This document corrects that error.

**FOR FURTHER INFORMATION CONTACT:**

Lisa Granger, Office of Policy and Planning, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 32, rm. 3330, Silver Spring, MD 20993-0002, 301-796-9115.

**SUPPLEMENTARY INFORMATION:**

In the *Federal Register* of Tuesday, May 19, 2015, in FR Doc. 2015-11983, the following correction is made:

1. On page 28622, in the second column, in the *ADDRESSES* section of the document, under *Instructions,* “Docket No. FDA-2013-N-1524” is corrected to read “Docket No. FDA-2015-N-1196”.

Dated: June 18, 2015.

Leslie Kux,

Associate Commissioner for Policy.